Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Foot Ankle Surg ; 55(2): 230-4, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26620421

RESUMEN

The purpose of the present retrospective study was to evaluate the outcomes (ie, ulcer recurrence, major amputation, death) in diabetic patients undergoing Chopart amputation because of deep infection or gangrene extending to the midfoot. From 2009 to 2011, 83 patients, aged 71.4 ± 9.3 years, underwent a midtarsal amputation and were followed up until December 31, 2012 (mean follow-up 2.8 ± 0.8 years). Of the 83 patients, 26 were female, 61 required insulin, 47 had renal insufficiency, 19 underwent hemodialysis, 65 had hypertension, 34 had a history of cardiac disease, and 4 had a history of stroke. Chopart amputation was performed in 38 patients (45.8%) with gangrene, 31 (37.4%) with abscess, and 14 (16.9%) with osteomyelitis. Urgent surgery was performed in 56 patients (67.5%). Effective revascularization was performed in 64 patients (77.1%) patients. Of the 83 patients, 47 had healed at a mean period of 164.7 (range 11 to 698) days. Ulcer recurrence developed in 15 patients (31.9%). A major amputation was necessary in 23 patients (27.7%), with an annual incidence of 13.0%. None of the included variables on logistic regression analysis was significantly associated with proximal amputation. Of the 83 patients, 38 (45.8%) died, with an annual incidence of 25.8%. On logistic regression analysis, age (odds ratio [OR] 1.11, 95% confidence interval [CI] 1.01 to 1.16), history of stroke (OR 9.94, 95% CI 3.16 to 31.24), and urgent surgery (OR 2.60, 95% CI 1.14 to 5.93) were associated with mortality. Chopart amputation represents the last chance to avoid major amputation for diabetic patients with serious foot complications. Our success rate was great enough to consider Chopart amputation a viable option for limb salvage in this high-risk population.


Asunto(s)
Amputación Quirúrgica , Pie Diabético/cirugía , Absceso/etiología , Absceso/cirugía , Anciano , Anciano de 80 o más Años , Amputación Quirúrgica/efectos adversos , Pie Diabético/complicaciones , Pie Diabético/fisiopatología , Femenino , Gangrena/etiología , Gangrena/cirugía , Humanos , Recuperación del Miembro , Masculino , Persona de Mediana Edad , Osteomielitis/etiología , Osteomielitis/cirugía , Estudios Retrospectivos , Resultado del Tratamiento , Cicatrización de Heridas
2.
Neuropsychobiology ; 72(1): 29-36, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26337616

RESUMEN

The effects of olanzapine and haloperidol on metabolic parameters in bipolar patients have been evaluated much less comprehensively than in schizophrenic patients. Therefore, in this study, medical records of 343 schizophrenic and bipolar patients treated with haloperidol or olanzapine for 1 year were retrospectively reviewed and metabolic outcomes were evaluated. After 12 months of follow-up, 25.9% of patients showed ≥3 metabolic abnormalities with a point prevalence of 27.2% in the bipolar and 24.9% in the schizophrenic group: 22.0% of the schizophrenic patients treated with haloperidol and 29.8% of those treated with olanzapine achieved ≥3 metabolic alterations; in bipolar patients, these percentages were 15.8% of those treated with haloperidol and 37.8% of those treated with olanzapine (p < 0.0001). Significant changes were reported over time in fasting glucose, triglycerides and cholesterol blood levels, systolic and diastolic blood pressure, body weight, and BMI. Overall, a significant number of schizophrenic and bipolar patients treated with olanzapine showed ≥3 metabolic alterations in the first month of treatment when compared to those treated with haloperidol. Moreover, the number of olanzapine-treated patients developing metabolic changes in the first month was significantly higher in both diagnostic groups when compared to those who reached metabolic abnormal values in the subsequent 11 months. These data suggest that both antipsychotics could increase the metabolic risk in schizophrenic and bipolar patients with a higher prevalence in olanzapine-treated patients. On the other hand, olanzapine-treated patients seem to achieve metabolic abnormalities faster than haloperidol-treated subjects in both diagnostic groups.


Asunto(s)
Antipsicóticos/efectos adversos , Benzodiazepinas/efectos adversos , Trastorno Bipolar/tratamiento farmacológico , Haloperidol/efectos adversos , Enfermedades Metabólicas/inducido químicamente , Esquizofrenia/tratamiento farmacológico , Adulto , Análisis de Varianza , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Olanzapina , Escalas de Valoración Psiquiátrica , Estudios Retrospectivos , Índice de Severidad de la Enfermedad
3.
Ann Vasc Surg ; 28(7): 1729-36, 2014 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-24952297

RESUMEN

BACKGROUND: To compare demographic and clinical characteristics, revascularization, major amputation, and mortality among patients admitted to a diabetic foot center because of critical limb ischemia (CLI) during 1999-2003 (cohort 1) and 2009 (cohort 2). METHODS: During 1999-2003, 564 diabetic patients with CLI (cohort 1) were admitted to our center, and 344 patients (360 affected limbs) were admitted during 2009 (cohort 2). Data on demographic and clinical characteristics, revascularization by peripheral angioplasty (PTA) or bypass graft (BPG), major amputation, and mortality were recorded. RESULTS: Patients belonging to cohort 2 were older than patients of cohort 1 (P = 0.001). In cohort 2, there were more subjects requiring insulin (P = 0.008) and duration of diabetes was longer (P = 0.001); moreover, there were more patients requiring dialysis (P = 0.001), patients with history of stroke (P = 0.004), or foot ulcer (P = 0.001). No significant difference between the 2 groups was found concerning gender, metabolic control, hypertension, lipid values, neuropathy, and retinopathy. Occlusion was more frequent than stenosis in the posterior tibial (P < 0.001) and peroneal (P = 0.016) arteries. However, the revascularization rate did not differ (P = 0.318) between the 2 groups. Restenosis after PTA was not significantly different (P = 0.627), whereas BPG failure was significantly more frequent (P = 0.010) in cohort 2 (2009). Major amputation (P = 0.222) and mortality rate (P = 0.727) did not differ between the 2 groups. CONCLUSIONS: The severity of either foot lesions or patients comorbidities should be concomitantly assessed and taken into proper consideration when evaluating changes in the amputation rate among different studies or in different temporal settings.


Asunto(s)
Amputación Quirúrgica , Pie Diabético/mortalidad , Pie Diabético/cirugía , Isquemia/mortalidad , Isquemia/cirugía , Pierna/irrigación sanguínea , Anciano , Angioplastia , Implantación de Prótesis Vascular , Estudios de Cohortes , Comorbilidad , Femenino , Humanos , Recuperación del Miembro , Masculino , Factores de Riesgo , Índice de Severidad de la Enfermedad , Tasa de Supervivencia , Resultado del Tratamiento
4.
Front Artif Intell ; 7: 1366055, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38774832

RESUMEN

Background: Major Depressive Disorder (MDD) is a prevalent mental health condition characterized by persistent low mood, cognitive and physical symptoms, anhedonia (loss of interest in activities), and suicidal ideation. The World Health Organization (WHO) predicts depression will become the leading cause of disability by 2030. While biological markers remain essential for understanding MDD's pathophysiology, recent advancements in social signal processing and environmental monitoring hold promise. Wearable technologies, including smartwatches and air purifiers with environmental sensors, can generate valuable digital biomarkers for depression assessment in real-world settings. Integrating these with existing physical, psychopathological, and other indices (autoimmune, inflammatory, neuroradiological) has the potential to improve MDD recurrence prevention strategies. Methods: This prospective, randomized, interventional, and non-pharmacological integrated study aims to evaluate digital and environmental biomarkers in adolescents and young adults diagnosed with MDD who are currently taking medication. The study implements a sensor-integrated platform built around an open-source "Pothos" air purifier system. This platform is designed for scalability and integration with third-party devices. It accomplishes this through software interfaces, a dedicated app, sensor signal pre-processing, and an embedded deep learning AI system. The study will enroll two experimental groups (10 adolescents and 30 young adults each). Within each group, participants will be randomly allocated to Group A or Group B. Only Group B will receive the technological equipment (Pothos system and smartwatch) for collecting digital biomarkers. Blood and saliva samples will be collected at baseline (T0) and endpoint (T1) to assess inflammatory markers and cortisol levels. Results: Following initial age-based stratification, the sample will undergo detailed classification at the 6-month follow-up based on remission status. Digital and environmental biomarker data will be analyzed to explore intricate relationships between these markers, depression symptoms, disease progression, and early signs of illness. Conclusion: This study seeks to validate an AI tool for enhancing early MDD clinical management, implement an AI solution for continuous data processing, and establish an AI infrastructure for managing healthcare Big Data. Integrating innovative psychophysical assessment tools into clinical practice holds significant promise for improving diagnostic accuracy and developing more specific digital devices for comprehensive mental health evaluation.

5.
Recenti Prog Med ; 111(7): 411-414, 2020.
Artículo en Italiano | MEDLINE | ID: mdl-32658880

RESUMEN

CoViD-19 is a disease caused by the novel coronavirus (SARS-CoV-2), originated from China in December 2019. In March 2020, CoViD-19 was declared a pandemic, having spread all over the word. The psychological impact of CoViD-19 disease must be recognized alongside the physical symptoms for all those affected. Furhermore quarantine for coronavirus has serious psychological side effects, such as depression and anxiety that are more likely to occur and worsen. Furhermore quarantine reduces the availability of psychiatric and psychological interventions. The evidence base for telepsychiatry is growing in adults and adolescents. A growing body of literature suggests that use of telepsychiatry to provide mental health services has the potential to remove geographic barriers between patients and providers and improves quality care. It has increased the volume of patients that physicians can reach and diagnose, as well as allowing them to treat patients.


Asunto(s)
Betacoronavirus , Infecciones por Coronavirus/psicología , Servicios de Salud Mental/organización & administración , Pandemias , Neumonía Viral/psicología , Psiquiatría/métodos , Estrés Psicológico/etiología , Telemedicina/métodos , Adolescente , Adulto , Anciano , Ansiedad/etiología , Actitud del Personal de Salud , Actitud Frente a la Muerte , COVID-19 , Cuidadores/psicología , Niño , Comorbilidad , Infecciones por Coronavirus/epidemiología , Depresión/etiología , Personal de Salud/psicología , Accesibilidad a los Servicios de Salud , Humanos , Trastornos Mentales/epidemiología , Trastornos Mentales/terapia , Neumonía Viral/epidemiología , Psiquiatría/organización & administración , Psicología del Adolescente , Psicología Infantil , Cuarentena/psicología , SARS-CoV-2
6.
Clin Schizophr Relat Psychoses ; 12(4): 185-188, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-27996318

RESUMEN

Clozapine-related pericarditis is a rare side effect of the drug. We reported the clinical cases of two women, aged 22 and 28 years, affected by schizophrenia with pericarditis symptoms related to clozapine treatment of 200 mg/day. Clozapine was discontinued in both patients, resulting in normalization of the ECG changes, and echocardiography confirmed the progressive disappearance of the pericardial effusion. Interestingly, while inflammatory indices and pro-brain natriuretic peptide (pro-BNP) plasma levels were high in both patients, only one of them showed tachycardia, subjective chest pain, shortness of breath and dyspnea, with a clinical symptomatology suggesting a cardiac involvement. BNP is a vasoactive peptide synthetized by the ventricular myocardium which splits in two fragments: BNP and the N-terminal (pro-BNP). Both are considered valuable biomarkers in clinical practice for the prediction of disease state and prognosis in patients with suspected heart failure. Pro-BNP acts as a key regulator in the homeostasis of water and salt excretion and in the maintenance of blood pressure, mainly by inhibiting the renin-angiotensin-aldosterone axis and blocking the sympathetic nervous activity. In our cases, pro-BNP plasma levels proved to be a profitable way to identify subjects with asymptomatic cardiac impairment who could benefit from a therapy preventing progression to heart failure.


Asunto(s)
Clozapina , Insuficiencia Cardíaca , Péptido Natriurético Encefálico , Esquizofrenia , Adulto , Biomarcadores , Clozapina/efectos adversos , Femenino , Insuficiencia Cardíaca/inducido químicamente , Humanos , Péptido Natriurético Encefálico/análisis , Esquizofrenia/tratamiento farmacológico , Adulto Joven
7.
Recenti Prog Med ; 108(2): 83-89, 2017 Feb.
Artículo en Italiano | MEDLINE | ID: mdl-28287202

RESUMEN

INTRODUCTION: Purpose of the study was to analyze the quality of life and psychiatric symptomatology in patients suffering from Inflammatory Bowel Diseases. METHODS: In this study were enrolled 108 patients: 67 cases (Ulcerative Colitis in 39 patients, Crohn's Disease in 28 cases) and 41 controls (patients suffering from Irritable Bowel Syndrome). Patients were subjected to Self-Report Symptom Inventory-Revised (SCL-90-R) to analyze general psychiatric symptomatology; Hamilton Depression Rating Scale (HAM-D) to analyze depressive symptomatology; Short Form-36 (SF-36) to evaluate the quality of life. RESULTS: Patients suffering from Inflammatory Bowel Disease have major limitations in phisical activities; they complain about daily activities; they consider their general health as the most poor and destined to deteriorate further in time. Patients suffering from Ulcerative Colitis have greater impairment if compared with Crohn's disease patients. CONCLUSION: Patients suffering with inflammatory bowel disease have a significant impairment in several areas of life quality and a psychiatric symptomatology that shows emotional - psycological discomfort due to the underlying disease.


Asunto(s)
Colitis Ulcerosa/psicología , Enfermedad de Crohn/psicología , Síndrome del Colon Irritable/psicología , Calidad de Vida , Actividades Cotidianas/psicología , Adolescente , Adulto , Anciano , Estado de Salud , Humanos , Persona de Mediana Edad , Escalas de Valoración Psiquiátrica , Adulto Joven
9.
Psychiatry Res ; 256: 275-282, 2017 10.
Artículo en Inglés | MEDLINE | ID: mdl-28651220

RESUMEN

Blood dyscrasias excluding agranulocytosis received limited attention in antipsychotic-treated patients during the first 18 weeks of therapy, although severe clinical conditions have been reported in a few cases. We extracted data records of 285 Caucasian patients after 18 weeks of antipsychotic treatments to investigate risk factors of blood dyscrasias. We observed a higher risk to develop both transient and persistent anemia, neutrophilia and eosinophilia in clozapine-treated patients, whereas in those treated with other atypical antipsychotics when compared to a reference group under typical antipsychotics, emerged an increased risk for transient neutrophilia and eosinophilia. Male patients revealed a higher risk of persistent eosinophilia, neutrophilia, and leukocytosis. Concomitant treatments with mood stabilizers or benzodiazepines proved to be risk factors for transient anemia, antidepressants for transient eosinophilia. Severe complications emerged in 3 cases of agranulocytosis. Cross-tabulation analysis showed a higher probability of a poor response in clozapine-treated patients with persistent anemia and a positive with persistent neutrophilia and eosinophilia. Our data evidenced that emerging blood dyscrasias were not associated with critical adverse effects, and only agranulocytosis required a treatment interruption. Other atypical antipsychotics might represent a viable alternative to potentially harmful clozapine and typical antipsychotics at the onset of life-threatening haematological alterations.


Asunto(s)
Antipsicóticos/efectos adversos , Clozapina/efectos adversos , Paraproteinemias/inducido químicamente , Adulto , Agranulocitosis/inducido químicamente , Benzodiazepinas/efectos adversos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Factores de Tiempo
10.
Riv Psichiatr ; 51(3): 96-103, 2016.
Artículo en Italiano | MEDLINE | ID: mdl-27362820

RESUMEN

OBJECTIVE: Monitoring drug-related side effects in psychiatric patients is highly recommended. In fact, frequent exposure to long-term polipharmacotherapy, poor compliance to pharmachological treatment and comorbidity with organic illnesses requiring the prescription of other drugs are causes of pharmacokinetic/pharmacodynamic interactions. These vulnerability factors result in a certain increase in adverse drug reactions (ADRs). METHODS: This study performes an analysis of Italian Medicine Agency data, in the section "signal analysis", to attempt an assessment of the safety warnings among the different psychotropic drug classes, belonging to the ATC class: N03 (antiepileptics), N05 (antipsychotics), N06 (psycho-analectic drugs). Then we analysed, in a descriptive way, the different association between the drug and the related ADR, evaluating the different safety profiles, in relation to experimental studies, supporting the importance of the signal. RESULTS: In the last years, among the new 25 ADRs, 10 were related to antidepressant drugs (8 SSRI, 1 mirtazapine, 1 agomelatine). In relation to antipsychotic drugs, 6 new correlations were found between drug and ADR onset, mainly among atypical antispychotics. Other correlations (6 above all) were found among antiepileptic drugs. Among benzodiazepines, a signal linked to rabdomylysis onset was found. It is also recommended an evaluation of safety profile in relation to zolpidem prescription. DISCUSSION: The results of our systematic review are a motivational input, considering the continuous increase of safety warnings, to attentively monitor drug's prescription. Spontaneous ADRs' signaling is a classical system to provide the required attention in relation to a potential risk. The clinician in charge must report this because he is the key figure in the drugs' safety process. CONCLUSIONS: In psychiatry, in which a long-term pharmachological therapy is frequent, clinicians are requested to find and signal ADRs to the competent authority.


Asunto(s)
Antidepresivos/efectos adversos , Antipsicóticos/efectos adversos , Prescripciones de Medicamentos , Psiquiatría , Anticonvulsivantes/efectos adversos , Humanos , Italia
11.
BMJ Case Rep ; 20152015 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-26032702

RESUMEN

Anecdotal evidence tends to suggest clozapine treatment as a cause of leucocytosis in schizophrenic patients, however, no conclusive evidence is available on this topic. We report the clinical cases of two schizophrenic men who were diagnosed with clozapine-related leucocytosis. The clozapine treatment was performed at a dose between 200 and 400 mg/day. When leucocytosis appeared, there was a loss of response to clozapine in both patients. Clozapine-induced leucocytosis in schizophrenic patients could be correlated to occurrence of psychotic symptomatology.


Asunto(s)
Antipsicóticos/efectos adversos , Clozapina/efectos adversos , Leucocitosis/inducido químicamente , Esquizofrenia/tratamiento farmacológico , Adulto , Antipsicóticos/administración & dosificación , Clozapina/administración & dosificación , Relación Dosis-Respuesta a Droga , Humanos , Leucocitosis/diagnóstico , Masculino , Valor Predictivo de las Pruebas , Esquizofrenia/fisiopatología , Resultado del Tratamiento
12.
Riv Psichiatr ; 49(3): 152-5, 2014.
Artículo en Italiano | MEDLINE | ID: mdl-25000892

RESUMEN

The authors, after examining a clinical case of obsessive-compulsive disorder, associated to Pica syndrome, analyse psychopathological development of the symptomatology in its complex, refuting some statements of published studies, that include Pica within obsessive-compulsive disorder spectrum. On the contrary, they think the coexistence of the two symptomatologies simply as an expression of a comorbidity, explaining why they are prone to link Pica with eating disorders.


Asunto(s)
Pica/diagnóstico , Pica/psicología , Femenino , Humanos , Persona de Mediana Edad , Trastorno Obsesivo Compulsivo/complicaciones , Pica/complicaciones
13.
Diabetes Res Clin Pract ; 103(2): 292-7, 2014 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-24492022

RESUMEN

AIMS: To investigate the effect of combined treatment with angiotensin-converting enzyme inhibitors (ACE) and statins on mortality in diabetic patients with critical limb ischemia (CLI). METHODS: Prospective observational study of 553 consecutive diabetic patients admitted because of CLI followed for a mean of 2.2 years. All patients underwent peripheral revascularization and antithrombotic therapy was prescribed or continued and therapy with statin and ACE was recorded. Mortality from any cause was assessed and Kaplan-Meier analyses were performed to compare the relationship between survival and recorded variables. RESULTS: One hundred thirty-nine patients did not have therapy with statin or an ACE, 78 had therapy with statin without ACE, 164 had therapy with ACE without statin and 172 patients had therapy with both statin and ACE. One hundred thirty-six patients died, 45/139 with neither statin nor ACE, 40/164 with ACE only, 26/78 with statin only, and 25/172 with both statin and ACE. Multivariate analysis confirmed the independent role of age, history of stroke, renal insufficiency and dialysis. Combined treatment with ACE and statin appeared to have a protective role. CONCLUSIONS: In patients with diabetes and CLI mortality after two years is high. Life expectancy was better in patients receiving combined therapy with ACE and statin but not with therapy with only a statin or an ACE.


Asunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Diabetes Mellitus/tratamiento farmacológico , Diabetes Mellitus/mortalidad , Pie Diabético/tratamiento farmacológico , Pie Diabético/mortalidad , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Anciano , Anciano de 80 o más Años , Quimioterapia Combinada , Femenino , Humanos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Prospectivos , Diálisis Renal , Resultado del Tratamiento
14.
Int J Antimicrob Agents ; 41(5): 468-72, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23473943

RESUMEN

A retrospective analysis of data from patients receiving daptomycin as outpatient parenteral antimicrobial therapy (OPAT) within the European Cubicin Outcomes Registry and Experience (EU-CORE(SM)) was performed. Of 4592 enrolled patients in 15 countries, 550 (12%) received daptomycin OPAT. Of these, 149 (27%) received daptomycin without hospital admission, 84% had significant underlying diseases and 44% were ≥65 years of age. Most frequently treated infections were complicated skin and soft-tissue infections (28%), osteomyelitis (17%), foreign body/prosthetic infections (15%) and endocarditis (14%). In patients with culture results available, Staphylococcus aureus and coagulase-negative staphylococci were the most commonly isolated primary pathogens [n = 218 (46%) and n = 102 (21%), respectively]. Daptomycin was typically used at doses of 6 mg/kg (n = 210; 38%) and 4 mg/kg (n = 160; 29%), with concomitant antibiotics used in 41%. The median treatment duration was 22 days (range 1-300 days), with a median of 13 OPAT days (range 1-290 days). Overall clinical success was observed in 89%, with high success rates across the wide range of infections, including those caused by meticillin-resistant and meticillin-susceptible S. aureus (88% and 90%, respectively). Daptomycin exhibited a favourable safety profile; 3.1% of patients discontinued treatment owing to an adverse event. These data demonstrate that daptomycin is effective and well tolerated in the treatment of a wide range of Gram-positive infections in the outpatient setting. Ease of administration of daptomycin, via a daily 2-min injection, and its efficacy and safety combine to make it an attractive treatment option for OPAT.


Asunto(s)
Atención Ambulatoria/métodos , Antibacterianos/administración & dosificación , Infecciones Bacterianas/tratamiento farmacológico , Daptomicina/administración & dosificación , Anciano , Anciano de 80 o más Años , Europa (Continente) , Femenino , Humanos , Inyecciones Intravenosas , Masculino , Persona de Mediana Edad , Pacientes Ambulatorios , Estudios Retrospectivos , Resultado del Tratamiento
15.
J Chemother ; 24(2): 113-21, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22546768

RESUMEN

The purpose of this study was to evaluate post-marketing efficacy and safety data for therapy with daptomycin (DAP) in Italy. Data from patients treated with DAP at 30 centres between January 2006 and July 2009 were analysed according to the protocol of the EU-CORE(SM). In 359 patients, DAP was most commonly prescribed for skin and skin-structure infections (55%), infective endocarditis (13%), and bacteraemia (12.5%). DAP was associated with rapid improvement, and clinical success rates ranging from 77 to 91%, despite almost half of the patient population being ≥65 years of age, 86% having significant underlying disease, and many being affected by drug-resistant pathogens. Staphylococcus aureus represented 35% of all pathogens isolated. Success rates for all staphylococcal and enterococcal infections were >80%, including methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus (MSSA). Clinical outcomes were similar for DAP whether used as first- or second-line therapy. DAP was well tolerated even with prolonged treatment.


Asunto(s)
Antibacterianos/uso terapéutico , Bacteriemia/tratamiento farmacológico , Daptomicina/uso terapéutico , Endocarditis Bacteriana/tratamiento farmacológico , Bacterias Grampositivas/efectos de los fármacos , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Anciano , Bacteriemia/microbiología , Endocarditis Bacteriana/microbiología , Femenino , Bacterias Grampositivas/crecimiento & desarrollo , Bacterias Grampositivas/aislamiento & purificación , Infecciones por Bacterias Grampositivas/microbiología , Humanos , Masculino , Estudios Retrospectivos , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA